Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7948)
All Articles published online
|
Publishing Process of This Article
|
Jun 21, 2016 (publication date) through Dec 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Martchenko K, Schmidtmann I, Thomaidis T, Thole V, Galle PR, Becker M, Möhler M, Wehler TC, Schimanski CC. Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. World J Gastroenterol 2016; 22(23): 5400-5405 [PMID: 27340356 DOI: 10.3748/wjg.v22.i23.5400] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v22/i23/5400.htm |
| Number | Citing Articles |
| 1 |
Ling Wang, Jin Wang, Ling Chen. TIMP1 represses sorafenib-triggered ferroptosis in colorectal cancer cells by activating the PI3K/Akt signaling pathway. Immunopharmacology and Immunotoxicology 2023; 45(4): 419 doi: 10.1080/08923973.2022.2160731
|
| 2 |
H. K. Yosef, T. Frick, M. K. Hammoud, A. Maghnouj, S. Hahn, K. Gerwert, S. F. El-Mashtoly. Exploring the efficacy and cellular uptake of sorafenib in colon cancer cells by Raman micro-spectroscopy. The Analyst 2018; 143(24): 6069 doi: 10.1039/C8AN02029A
|
| 3 |
Francesca Mastropasqua, Flaviana Marzano, Alessio Valletti, Italia Aiello, Giuseppe Di Tullio, Annalisa Morgano, Sabino Liuni, Elena Ranieri, Luisa Guerrini, Giuseppe Gasparre, Elisabetta Sbisà, Graziano Pesole, Antonio Moschetta, Mariano Francesco Caratozzolo, Apollonia Tullo. TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours. Molecular Cancer 2017; 16(1) doi: 10.1186/s12943-017-0634-7
|
| 4 |
Thomas J. George, Alison M. Ivey, Azka Ali, Ji-Hyun Lee, Yu Wang, Karen C. Daily, Brian H. Ramnaraign, Sanda A. Tan, Krista P. Terracina, Thomas E. Read, Long H. Dang, Atif Iqbal. Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer. The Oncologist 2021; 26(5): 362 doi: 10.1002/onco.13689
|
| 5 |
Alexander Burov, Ekaterina Grigorieva, Timofey Lebedev, Valeria Vedernikova, Vladimir Popenko, Tatiana Astakhova, Olga Leonova, Pavel Spirin, Vladimir Prassolov, Vadim Karpov, Alexey Morozov. Multikinase inhibitors modulate non-constitutive proteasome expression in colorectal cancer cells. Frontiers in Molecular Biosciences 2024; 11 doi: 10.3389/fmolb.2024.1351641
|
| 6 |
Ronghui Cheng, Hongmei Yong, Yunhong Xia, Qingsong Xie, Guangyi Gao, Xueyi Zhou. Chemotherapy regimen based on sorafenib combined with 5-FU on HIF-1α and VEGF expression and survival in advanced gastric cancer patients. Oncology Letters 2017; 13(4): 2703 doi: 10.3892/ol.2017.5769
|
| 7 |
Flaviana Marzano, Mariano Francesco Caratozzolo, Graziano Pesole, Elisabetta Sbisà, Apollonia Tullo. TRIM Proteins in Colorectal Cancer: TRIM8 as a Promising Therapeutic Target in Chemo Resistance. Biomedicines 2021; 9(3): 241 doi: 10.3390/biomedicines9030241
|